· Original article ·

Intravitreal treatment realities and experiences in diabetic macular edema

Cemal Çavdarli, Firat Selen, Pinar Topcu Yilmaz, Mehmet Numan Alp

Department of Ophthalmology, Ankara Numune Training and Research Hospital, Ankara 06230, Turkey
Correspondence to: Cemal Çavdarli. Department of Ophthalmology, Ankara Numune Training and Research Hospital, Ankara 06230, Turkey. ccavdarli@gmail.com

玻璃体腔抗 VEGF 治疗糖尿病性黄斑水肿的疗效分析

Cemal Çavdarli, Firat Selen, Pinar Topcu Yilmaz, Mehmet Numan Alp
(作者单位:06230 土耳其安卡拉, Ankara Numune 教学研究医院眼科)
通讯作者:Cemal Çavdarli. ccavdarli@gmail.com

摘要

目的:评估玻璃体腔内抗 VEGF 治疗糖尿病黄斑水肿(DME)24mo 后的现实生活剖析和视觉效果。
方法:本研究包括了 2012-06/2016-12 接受玻璃体腔内注射的视网膜内和/或视网膜下液体和基线中心黄斑厚度(CMT)超过 300μm 的 DME 患者。在基线处 3,6,12,18 和 24mo 评估视力(VA)和 CMT 的变化,以及患者就诊和玻璃体腔内注射总数。
结果:研究包含 40 例患者(54 眼)。基线处 3mo LogMAR 视力从 0.67±0.47 提高到 0.59±0.43 并在 12mo 内保持 3.5±2.19 次注射。12mo 和 24mo 时平均就诊次数分别为 9±2.39 和 15.48±4.84。基线处平均 CMT 为 450±153μm, 12mo 和 24mo 时分别降至 385±141μm 和 305±111μm ($P<$ 0.001)。
结论:PRN 方法在治疗 DME 中可以保持视力稳定并改善黄斑水肿,但在主动疗法中,较低的就诊负担可能会获得类似的或更好的治疗效果。
关键词:糖尿病黄斑水肿;玻璃体腔注射;光学相干断层扫描;现实生活

Abstract

• AIM: To evaluate the real life anatomical and visual outcome after intravitreal anti-VEGF treatment in diabetic macular edema (DME) throughout 24mo.
• METHODS: Treatment naive central-involved DME patients with intraretinal and/or subretinal fluid and baseline central macular thickness (CMT) over 300μm in spectral domain optic coherence tomography scans who received intravitreal injections between June 2012 and December 2016 were included in the study. The changes in visual acuity (VA) and CMT, and total number of patient visits and intravitreal injections were assessed in the baseline of 3, 6, 12, 18 and 24mo.
• RESULTS: Totally 54 eyes of 40 patients were included. VA at baseline improved from 0.67±0.47 LogMAR to 0.59±0.43 LogMAR at 3mo and maintained with 3.5±2.19 injections throughout 12mo. The average number of visits was 9±2.39 and 15.48±4.84 at 12mo and 24mo, respectively. The mean CMT at baseline was 450±153μm and decreased to 385±141μm and 305±111μm at 12 and 24mo, respectively ($P<0.001$).
• CONCLUSION: Pro re nata (PRN) approach in DME treatment may keep the VA stable and reduce macular edema, but probably similar or better treatment effectivity could be obtained with a lower visit burden in proactive regimens.
• KEYWORDS: diabetic macular edema; intravitreal injection; optical coherence tomography; real life

INTRODUCTION

Diabetes mellitus (DM) is a global health disease and has an increasing prevalence worldwide. The ophthalmic manifestation diabetic macular edema (DME) is one of the major causes of visual impairment[1]. DME can emerge within the first five years of type 1 diabetes. The DME prevalence increases from 0-3% to 28-29% in patients who have type 2 diabetes for 20y[2-3]. It is estimated that nearly 750,000 people are affected by this central vision-threatening disease in the United States. As well, DME will cause at least three lines of visual loss in 24% of eyes in 3y[4-5]. In DME, mostly vascular endothelial growth factor (VEGF) and other inflammatory factors like interleukin-6, intercellular adhesion molecule-1, and monocyte chemotactic protein-1, have been considered responsible from abnormal vascular permeability[6-7]. In the majority of patients, macular laser photocoagulation is inadequate in visual improvement[8]. RIDE and RISE, READ-2, RESTORE and RESOLVE were ranibizumab based randomized controlled clinical trials in

which outstanding visual outcomes were achieved with ranibizumab when compared with macular laser or sham injection[9-12]. Recently, the three commonly used intravitreal VEGF inhibitors, bevacizumab（Avastin, Genentech）, ranibizumab（Lucentis, Genentech）, aflibercept（Eylea, Regeneron Pharmaceuticals）, and the slow－release intravitreal steroid dexamethasone implant（Ozurdex, Allergan）have been shown to be safe and effective for DME treatment[13-16]. Aflibercept, ranibizumab, and dexamethasone implant are Food and Drug Administration（FDA）approved for DME treatment but bevacizumab which has not been approved for any ocular indication is widely used off-label[17]. Visual gain and the benefits of anti-VEGF therapies of DME are evaluatedclearly in pivotal studies but "Can we obtain those results in real life under real－life limitations?" The purpose of this study is to explore the real life experiences and outcomes in DME patients who were treated with bevacizumab, ranibizumab or aflibercept.

SUBJECTS AND METHODS

All patients from Ankara Numune Training and Research Hospital Retina Service who had received an initial intravitreal anti－VEGF treatment related to central－involved diabetic macular edema, and had follow-up duration over than 6mo after the injection between June 2012 and December 2016 were selected. This study was designed as a cross-sectional retrospective study and followed the tenets of the Declaration of Helsinki and carried out with ethical approval from the Institutional Ethics Committee. The real life data were captured from patient records which were investigated retrospectively.

Each patient had bilateral assessment for the median logarithm of the minimal angle of resolution（LogMAR）visual acuity（VA）converted from Snellen measurements, anterior segment and fundus examination and spectral domain optical coherence tomography（SD-OCT）Zeiss Cirrus HD-OCT 4000（Carl Zeiss Meditec AG, Germany）6×6 mm scans for macular morphology and thickness at each visit scheduled 1mo apart. SD-OCT image database was used to assess the retinal images with reports.

All patients were also evaluated with fundus fluorescein angiography. Patients with non－proliferative diabetic retinopathy who had central macular thickness（CMT）over than 300 μm with intraretinal and/or subretinal fluid in SD-OCT and best-corrected visual acuity between 1.2 LogMAR and 0.3 LogMAR were included in the study. A standard or fixed treatment protocol wasn't followed, and all the treatment decisions were given according to patient requirements. An appointment system was used to perform all intravitreal injections within 1 to 5d after the last visit in an operating room. Then, patients were recalled at 1mo intervals. Retreatment with an intravitreal anti-VEGF was planned when the central macular thickness was >300 μm in OCT scans with remaining intraretinal and/or subretinal fluid in the follow-up visit. A dry macula was defined as CMT ≤300 μm without


Figure 1　Changes of LogMAR vision acuity between baseline and 24mo.

any residual fluid or with some small amount of cystoid cavities in the fovea resembling a chronic degenerative change but unlike a cystoid macular edema. Switching to another anti－VEGF, laser rescue therapy or intravitreal steroid implant were discussed in persistent DME cases who had less than 10% decrement in CMT after 3 or 4 monthly intravitreal anti－VEGF injections without a visual gain. Patients who received intravitreal steroids were not included in the study. A laser rescue therapy（as deferred laser therapy）with PASCAL Streamline Yellow（wavelength, 577 nm）was planned six months（24wk）after the initial intravitreal therapy[18].

Currently, we use individualized therapies of proactive regimens, but during the study period, our treatment regimen fitted more to the pro re nata（PRN）approach of the anti－VEGF treatment of DME. Subjects having an epiretinal membrane, vitreomacular traction, vitreous haemorrhage, proliferative diabetic retinopathy, fluorescein angiographic macular ischemia, any type of age－related macular degeneration, degenerative myopia, uveitis, previous trauma, and posterior segment surgery or intraocular surgery, past laser history or sequential intravitreal injections, less than 6mo follow-up were excluded from the study.

Visual acuity, CMT, the number of total visits and injections at baseline and months 3rd, 6th, 12th, 18th, and 24th were the assessment parameters.

Statistical analyses were performed with the SPSSversion 17.0（SPSS Inc., Chicago, IL）. The Related Samples Wilcoxon Signed Rank Test was used to determine the statistical significance of the changes in the VA and SD-OCT. A value of $P < 0.05$ was considered statistically significant. Other results were given as means±SD.

RESULTS

Fifty-four eyes of 40 patients were included in the study. 22 of the total subjects（55%）were female and 18（45%）were male. The mean ages were 60.59±8.9 and 62.3±11.17 years in female and male subjects, respectively. The mean duration of diabetes mellitus was 14.7±4.9y. The mean follow up time was 21.22±6.88mo. 14 eyes had local peripheral ischemic pattern in their four quadrant fluorescein angiographic images. None of them had macular ischemic pattern in their fluorescein angiography.

The changes of LogMAR vision during the follow-up period is given in Figure 1. The differences in visual acuity between baseline and 3rd, 6th, 12th, 18th and 24th months were not

**Figure 2　Mean total injections and visit numbers in 3, 6, 12, 18 and 24mo.**

Figure 3　Changes of central macular thickness between baseline and 24mo.

statistically significant ($P > 0.05$, Wilcoxon Signed Ranks Test).

The mean number of intravitreal injections was 3.52 ± 2.19 and 6.15 ± 3.65 in the 12 and 24mo, respectively. The average number of patient visits were 9.0 ± 2.39 in the 12mo, and 15.48 ± 4.8 in the 24mo follow-up (Figure 2).

The mean baseline CMT was 450 ± 153 μm and decreased to 385 ± 141 μm at 12mo. The final CMT was 305 ± 111 μm in the second year. The reduction in CMT at 3th , 6th , 12th , 18th and 24th months from baseline were statistically significant ($P = 0.001$, $P = 0.014$, $P < 0.001$, $P = 0.025$ and $P < 0.001$, respectively for Wilcoxon Signed Ranks Test, $P < 0.05$) (Figure 3).

Ranibizumab was the most frequently used intravitreal agent for DME. The peak of intravitreal treatment application term was between 6 – 12mo. Furthermore, the preference of bevacizumab injections decreased gradually while aflibercept preference increased throughout the second year. DME affected eyes receiving an intravitreal agent increased throughout the first year, and intravitreal treatment requirement continued at the same intensity in the second year (Figure 4).

Eleven eyes received laser rescue therapy (only focal treatment) between 6-12mo after the baseline assessment. 48 (89%), 46 (85%) and 43 (80%) eyes completed the 12mo, 18mo and 24mo visits respectively. All the intravitreal treatment agents were tolerated well, and none of the patients had procedure-related serious adverse events.

DISCUSSION

This study investigates the real life outcomes of intravitreal

Figure 4　The intravitreal injection profile of anti - VEGF agents used for central-involved DME among 0-3mo, 3-6mo, 6-12mo, 12-18mo and 18-24mo.

anti – VEGF treatment in DME patients under real – life limitations and decisions. Visual gain is one of the primary goals of intravitreal anti-VEGF treatment in DME, and the visual gain was maximum in the third and twelfth month of this study. Throughout the second year, the visual gain achievement was relatively maintained with intravitreal treatment and VA was fixed slightly above the baseline value. The first real life data was from ADMOR study that assessed ranibizumab efficacy in South Asian DME patients[19]. Also, Hrarat et al[20] reported a mean gain of 10.7 letters at the 12mo of the treatment in a real life study with ranibizumab. The best corrected visual acuity (BCVA) changed from 48.3 letters ($20/100 = 0.7$ LogMAR) to 59 letters ($20/63 = 0.5$ LogMAR) in this study. Vyas et al[21] found that the VA increased from 0.80 LogMAR to 0.68 LogMAR at 6wk, 0.63 LogMAR at the 3mo and 0.6 LogMAR at the 6mo with bevacizumab injections. Mushtaq et al[22] found a mean visual gain of 0.12 LogMAR (6 letters) with bevacizumab injections at 12mo.

PRN treatment protocol is described as retreatment on proof of exudative disease activity on monthly visits. The intraretinal and/or subretinal fluid is a marker of disease activity and treatment requirement[23]. In a treat and extend (TAE) protocol, monthly injections are used until the exudation is resolved. Then, the time to retreatment is lengthened 1-2wk as long as a sign of recurrent exudation is absent. In patients with recurrence of exudation, treatment interval is reduced. In TAE protocol the main objective is to obtain and maintain a dry macula without recurrences as in PRN treatment. It is believed to reduce the treatment burden by fewer visits, diagnostics and therapeutics[24].

In the ranibizumab therapy arm of the RESTORE study; the mean number of injections in the 1st year was 7 injections. In the RELIGHT study, the patients received 8.5 injections over 18mo[11,25]. The mean number of injections in real life studies ranged between 3.3 to 5 over the 12mo follow-up period[22,26]. Our results are similar to the study by Mushtaq et al[22] with a mean of 3.52 ± 2.19 injections. Sugimoto et al[27] reported a mean of 8.8 TAE injections in 24mo period and we completed the second year with a mean of 6.16 ± 3.65 injections. They discussed that subjects with the TAE regimen required fewer office visits (range 7-9 in 2y) and had better vision stability.

We believe that our low mean injection values originated from more PRN approach.

Granström et al[26] resulted mean of 14 visits（10-19）and Hrarat et al[20] resulted mean of 8.8 visits（4-13）per a patient over the 12mo. We have approximate results with Hrarat, and we completed the second year with a mean of 15.48±4.84 visits, approximately 1.5mo apart between each visit. The patient visits for these long-term follow-up patients were stable and regular.

The mean baseline CMT reduction in OCT after intravitreal treatment was 10, 11 and 12% in the 3, 6 and 12mo respectively. It was completed with 30% at the end of the 2y. Mushtaq et al[22] found 33.6 μm OCT decrement in group 1（baseline CMT thickness <400 μm）and 146 μm in group 2（baseline CMT thickness >400 μm）in the first year. The CMT proportional reduction in group 1 was similar to our results for the first year. Also, mean CMT reduction from baseline to 12mo was 127±158 μm（approximately 30%）in RELIGHT study[25]. These results suggest that the decrease in CMT after intravitreal anti-VEGF treatment is higher in patients with higher baseline CMT if the baseline CMT is higher.

The major limitation of this study was the absence of a standard treatment model. Three different anti-VEGF forms were used to assess the effects of intravitreal therapy on whole functional and anatomical outcomes. The number of used anti-VEGFs（Figure 4）and clinical severity of diabetic macular edema in intravitreal treatment subgroups were not proportional to each other, so we couldn't compare the efficacy of intravitreal agents. However, it is evident that a unique treatment protocol of PRN, TAE or monthly regimen cannot be used in all subjects under real life clinical circumstances.

In DRCR net Protocol T, over 40% of study eyes required a deferred laser and more than 30% of ranibizumab-treated eyes（every 4wk in 24mo）needed a macular laser in phase 3 RISE and RIDE trials[9,17]. Currently, we think laser treatment is still an essential step in diabetic retinopathy and macular edema treatment and should be used in necessary conditions. Also, some of the ongoing studies focused on if the laser treatment can be used in combination with anti-VEGFs[28] to reduce intraocular VEGF-load, treatment burden and risks of intravitreal therapy while stabilizing DME. It has been shown that PRP reduces plasma VEGF levels in 4mo after treatment[29]. Also, it is known that the use of sub-threshold macular laser therapies causes minimal collateral damage, and when used in selectively targeted areas like peripheral ischemia they may provide better results both in diabetic retinopathy and DME treatment.

In general assessment, we believe that the number of visits was adequate in our study. If we accept VA and CMT as the criteria of success in the intravitreal treatment of DME, the first and second-year results are satisfactory. We maintained and protected the baseline VA. Also, we think it is a satisfactory result that 80% of the eyes completed the second year follow-up. This is likely to increase if sufficient awareness is raised about the severity of diabetic macular edema in patients. Mainly, in the first half of the study period, ranibizumab was the most available and frequently preferred anti-VEGF worldwide, as well it was the first approved anti-VEGF for DME by FDA. We think that was the most influential reason in the treatment decision and high ranibizumab percentages in our clinical applications. Also, clinicians moved away from off-label medicines while new and approved options became available（Figure 4）.

We believe that age, presence of systemic comorbidities, poor economic and social attainment to treatment, poor education, and awareness of the disease, uncontrolled diabetes, PRN treatment without loading dose applications, the presence of an appointment system for intravitreal injections are the most significant limitations for intravitreal treatment effectivity. As a result of more PRN approach in this study, the visit numbers are adequate, but according to pivotal studies' results, our injection numbers reflect undertreatment. So, a PRN protocol with loading doses or TAE of a proactive regimen might be an advantageous option to increase treatment effectivity or decrease treatment burden which was indicated in RETAIN study[30].

In conclusion, PRN approach in DME treatment may keep the VA stable and decrease CMT, but probably similar or better treatment effectivity could be obtained with a lower visit burden in proactive regimens.

REFERENCES

1 Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. *Bull World Health Organ* 2004;82(11):844-851

2 White NH, Sun WJ, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP, Davis MD, DCCT-EDIC Research Group. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. *Diabetes* 2010;59(5):1244-1253

3 Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. *Ophthalmology* 1984;91(12):1464-1474

4 Shea AM, Curtis LH, Hammill BG, Kowalski JW, Ravelo A, Lee PP, Sloan FA, Schulman KA. Resource use and costs associated with diabetic macular edema in elderly persons. *Arch Ophthalmol* 2008;126(12):1748-1754

5 Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. *JAMA* 2007;298(8):902-916

6 Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. *J Biol Chem* 1999;274(33):23463-23467

7 Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. *Ophthalmology* 2009;116(1):73-79

8 Boyer DS, Hopkins JJ, Sorof J, Ehrlich JS. Anti-vascular endothelial growth factor therapy for diabetic macular edema. *Ther Adv Endocrinol Metab* 2013;4(6):151-169

9 Brown DM, Nguyen QD, Marcus DM, Boyer D, Patel S, Feiner L, Schlottmann P, Rundle AC, Zhang JM, Rubio RG, Adamis AP, Ehrlich JS, Hopkins JJ. The RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. *Ophthalmology* 2013;120(10):2013-2022

10 Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, Boyer D, Heier JS, Abraham P, Thach AB, Lit ES, Foster BS, Kruger E, Dugel P, Chang T, Das A, Ciulla TA, Pollack JS, Lim JI, Eliott D, Eliot D, Campochiaro PA, READ- Study Group. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. *Ophthalmology* 2010;117(11):2146-2151

11 Mitchell P, Bandello F, Schmidt-Erfurth U, *et al*. The RESTORE Study Group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. *Ophthalmology* 2011;118(4):615-625

12 Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurrbusch UE, Gekkieva M, Weichselberger A, Wolf S. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. *Diabetes Care* 2010;33(11):2399-2405

13 Arevalo JF, Lasave AF, Wu L, Diaz-Llopis M, Gallego-Pinazo R, Alezzandrini AA, Berrocal MH. Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema. *Retina* 2013;33(2):403-413

14 Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. *Arch Ophthalmol* 2012;130(9):1145-1152

15 Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Brown DM. Intravitreal aflibercept for diabetic macular edema. *Ophthalmology* 2014;121(11):2247-2254

16 Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. *Ophthalmology* 2014;121(10):1904-1914

17 Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. *N Engl J Med* 2015;372(13):1193-1203

18 Diabetic Retinopathy Clinical Research Network, Elman MJ, Qin HJ, Aiello LP, Beck RW, Bressler NM, Ferris FL 3rd, Glassman AR, Maturi RK, Melia M. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. *Ophthalmology* 2012;119(11):2312-2318

19 Ghanchi F, Hazel CA. South Asian diabetic macular oedema treated with ranibizumab (ADMOR)-real-life experience. *Eye (Lond)* 2016;30(1):133-138

20 Hrarat L, Fajnkuchen F, Boubaya M, Lévy V, Sarda V, Grenet T, Nghiem-Buffet S, Chaine G, Giocanti-Auregan A. Outcomes after a 1-year treatment with ranibizumab for diabetic macular edema in a clinical setting. *Ophthalmologica* 2016;236(4):207-214

21 Vyas S, Thapa R, Bajimaya S, Pradhan E, Paudyal G. Anatomical and visual outcome of intravitreal bevacizumab (Avastin) in patients with diabetic macular edema. *Nepal J Ophthalmol* 2016;8(15):54-61

22 Mushtaq B, Crosby NJ, Dimopoulos AT, Lip PL, Stavrou P, El-Sherbiny S, Yang Y. Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema. *Clin Ophthalmol* 2014;8:807-812

23 Brown DM, Shapiro H, Pier Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration. *Retina (Philadelphia, Pa)* 2013;33(1):23-34

24 Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. *Ophthalmology* 2010;117(11):2134-2140

25 Pearce I, Banerjee S, Burton BJ, Chakravarthy U, Downey L, Gale RP, Gibson J, Pagliarini S, Patel J, Sivaprasad S, Andrews C, Brittain C, Warburton J, RELIGHT Study Group. Ranibizumab 0.5 mg for diabetic macular edema with bimonthly monitoring after a phase of initial treatment: 18-month, multicenter, phase IIIB RELIGHT study. *Ophthalmology* 2015;122(9):1811-1819

26 Granström T, Forsman H, Lindholm Olinder A, Gkretsis D, Eriksson JW, Granstam E, Leksell J. Patient-reported outcomes and visual acuity after 12 months of anti-VEGF-treatment for sight-threatening diabetic macular edema in a real world setting. *Diabetes Res Clin Pract* 2016;121:157-165

27 Sugimoto M, Ichio A, Nunome T, Kondo M. Two year result of intravitreal bevacizumab for diabetic macular edema using treat and extend protocol. *Medicine (Baltimore)* 2017;96(16):e6406

28 Mehta H, Gillies MC, Fraser-Bell S. Combination of vascular endothelial growth factor inhibitors and laser therapy for diabetic macular oedema: a review. *Clin Experiment Ophthalmol* 2016;44(4):335-339

29 Lip PL, Belgore F, Blann AD, Hope-Ross MW, Gibson JM, Lip GY. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. *Invest Ophthalmol Vis Sci* 2000;41(8):2115-2119

30 Prünte C, Fajnkuchen F, Mahmood S, Ricci F, Hatz K, Studnička J, Bezlyak V, Parikh S, Stubbings WJ, Wenzel A, Figueira J, RETAIN Study Group. Ranibizumab 0.5mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. *Br J Ophthalmol* 2016;100(6):787-795